novonordisk
Profit increased in the first quarter for Danish pharmaceutical company Novo Nordisk compared to the previous year. First-quarter net profit increased by 28% to 25.41 billion Danish kroner ($3 billion), the company reported. Earnings per share increased by 29% to 5.68 kroner. Operating profit increased by 27% in kroner and by 30% at constant exchange rates (CER) to 31.8 billion kroner. First quarter sales increased by 22% measured in kroner and by 24% at CER to 65.35 billion kroner in the first three months of 2024. For 2024, the company now expects operating profit growth to be 22% to 30% at ...
DPA International
Danish pharmaceutical firm Novo Nordisk said it has agreed to acquire the biotech company Cardior Pharmaceuticals, based in Hanover, Germany, for up to €1.03 billion ($1.01 billion), according to a joint announcement on Monday. Novo Nordisk, known primarily for its diabetes business and the weight-loss drugs Wegovy and Ozempic, intends to strengthen its presence in the field of cardiovascular diseases. The focus is particularly on a promising drug from Cardior for heart failure. Cardior was founded in 2016 as a spin-off from Hanover Medical School. The heart disease therapy developed by the st...
DPA International
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら